Introduction: Drug Discovery in the 21st Century

Drug Discovery Handbook

Volumn , Issue , 2005, Pages 1-10

  Gad, Shayne Cox ^a  

^a Gad Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889079977     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471728780     Document Type: Editorial

References (29)

1. Fishlock, D. (1990, April 24). Survival of the fittest drugs. Financial Times, pp. 16-17.
2. Gad, S. C. (1998b). A tier testing strategy incorporating in vitro testing methods for pharmaceutical safety assessment. Humane Innovations Alternatives Animal Experimentation, 3, 75-79.
3. Gad, S. C. (2001). In Vitro Toxicology, 2nd ed. Taylor and Francis, Philadelphia, PA.
4. Littlehales, C. (1999). The Price of a Pill, Modern Drug Discovery, Jan/Feb 1999, pp. 21-30.
5. O'Grady, J., Linet, O. I. (1990). Early Phase Drug Evaluation in Man. CRC Press, Boca Raton, FL.
6. Zbinden, G., Elsner, J., Boelsterli, U. A. (1984). Toxicological screening. Reg. Toxicol. Pharamcol. 4, 275-286.
7. Gad, S. C. (1988a). An approach to the design and analysis of screening studies in toxicology, J. Am. Coll. Of Toxicol. 7(2), 127-138.
8. Gad, S. C. (1989a). Principles of screening in toxicology:With special emphasis on applications to neurotoxicology, J. Am. Coll. Toxicol. 8(1), 21-27.
9. Tukey, J.W. (1977). Exploratory Data Analysis. Addison-Wesley, Reading, MA.
10. Redman, C. (1981). Screening compounds for clinically active drugs. In C. R. Buncher, J. Tsay (Eds), Statistics in the Pharmaceutical Industry. Marcel Dekker, New York, pp. 19-42.
11. Alder, S., Zbinden, G. (1988). National and International Drug Safety Guidelines. MTC Verlag, Zollikon, Switzerland.
12. Angell, M. (2004). The Truth About the Drug Companies. Random House, New York.
13. Beyer, K. (1978). Discovery, development and delivery of new drugs. Monographs in Pharmacology and Physiology, No. 12. Spectrum, New York.
14. FDA (Food and Drug Administration) (1987a). Good laboratory practice regulations: Final rule. 21 CFR Part 58, Fed. Reg., September 4, 1987.
15. FDA (Food and Drug Administration) (1987b). New drug, antibiotic, and biologic drug produce regulations. 21 CFR Parts 312, 314, 511, and 514, Federal Register, 52(53), 8798-8857.
16. French, S. (1982). Sequencing and Scheduling. Halsted, New York.
17. Gad, S. C. (2000). Product Safety Evaluation Handbook, 2nd ed. Marcel Dekker, New York.
18. Goozner, M. (2004). The $800 Million Pill. University of California Press, Los Angeles.
19. Guarino, R. A. (1987). New Drug Approval Process. Marcel Dekker, New York.
20. Hamner, C. E. (1982). Drug Development. CRC Press, Boca Raton, FL, pp. 53-80.
21. Kliem, R. L. (1986). The Secrets of Successful Project Management. Wiley, New York.
22. Knutson, J. R. (1980). How to Be a Successful Project Manager. American Management Associations, New York.
23. Leber, P. (1987). FDA: The federal regulations of drug development. In H. Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress. Raven, New York, pp. 1675-1683.
24. Levy, A. E., Simon, R. C., Beerman, T. H., Fold, R. M. (1977). Scheduling of toxicology protocol studies. Comput. Biomed. Res. 10, 139-151.
25. Matoren, G. M. (1984). The Clinical Process in the Pharmaceutical Industry. Marcel Dekker, New York, pp. 273-284.
26. Sneader, W. (1986). Drug Development: From Laboratory to Clinic. Wiley, New York.
27. Spector, R., Park, G. D., Johnson, G. F., Vessell, E. S. (1988). Therapeutic drug monitoring. Clin. Pharmacol. Therapeu. 43, 345-353.
28. Spilker, B. (1994). Multinational Drug Companies, 2nd ed. Raven, New York.
29. Zbinden, G. (1992). The Source of the River Po. Haag and Herschen, Frankfurt, Germany.